Cystatin C predicts diabetic retinopathy in Chinese patients with type 2 diabetes

详细信息    查看全文

• 作者：Shijie Sun ; Minglong Li ; Jie Zhou ; Zhibo Gai…
• 关键词：Cystatin C ; Diabetic retinopathy ; Type 2 diabetes ; Glomerular filtration rate
• 刊名：International Journal of Diabetes in Developing Countries
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：35
• 期：3-supp
• 页码：398-404
• 全文大小：271 KB
• 参考文献：1.Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol. 2002;86:716–22.PubMed PubMedCentral CrossRef
  2.Hirsch IB, Brownlee M. Beyond hemoglobin A1c-need for additional markers of risk factor for diabetic microvascular complications. JAMA. 2010;303:2291–2.PubMed CrossRef
  3.Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007;53:480–8.PubMed CrossRef
  4.Jeon YK, Kim MR, Huh JE, Mok JY, Song SH, Kim SS, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258–63.PubMed PubMedCentral CrossRef
  5.He R, Shen J, Zhao J, Zeng H, Li LX, Zhao JG, et al. High Cystatin C levels predict severe retinopathy in type 2 diabetes patients. Eur J Epidemiol. 2013;28:775–8.PubMed CrossRef
  6.Namperumalsamy P, Nirmalan PK, Ramasamy K. Developing a screening program to detect sight-threatening diabetic retinopathy in South India. Diabetes Care. 2003;26:1831–5.PubMed CrossRef
  7.Zhang H, Wang J, Ying GS, Shen L, Zhang Z. Diabetic retinopathy and renal function in Chinese type 2 diabetic patients. Int Urol Nephrol. 2014;46:1375–81.PubMed CrossRef
  8.Wilkinson CP, Ferris 3rd FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82.PubMed CrossRef
  9.Bandello F, Lattanzio R, Zucchiatti I, Del Turco C. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol. 2013;50:1–20.PubMed CrossRef
  10.Spranger J, Kroke A, Möhlig M, Hoffmann K, Bergmann MM, Ristow M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52:812–7.PubMed CrossRef
  11.Gardner TW, Antonetti DA, Barber AJ, Lanoue KF, Nakamura M. New insights into the pathophysiology of diabetic retinopathy: potential cell-specific therapeutic targets. Diabetes Technol Ther. 2000;2:601–4.PubMed CrossRef
  12.Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257–9.PubMed CrossRef
  13.Paraoan L, Hiscott P, Gosden C, Grierson I. Cystatin C in macular and neuronal degenerations: implications for mechanism(s) age-related macular degeneration. Vis Res. 2010;50:737–42.PubMed CrossRef
  14.Wassélius J, Johansson K, Håkansson K, Abrahamson M, Ehinger B. Cystatin C uptake in the eye. Graefes Arch Clin Exp Ophthalmol. 2005;243:583–92.PubMed CrossRef
  15.Van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300–6.PubMed CrossRef
  16.Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem. 2009;55:1932–43.PubMed CrossRef
  17.Mussap M, Plebani M. Biochemistry and clinical role of human Cystatin C. Crit Rev Clin Lab Sci. 2004;41:467–550.PubMed CrossRef
  18.The Diabetic Retinopathy Study Research Group. Preliminary report on the effects of photocoagulation therapy. Am J Ophthalmol. 1976;81:383–96.CrossRef
  19.The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy; clinical applications of Diabetic Retinopathy Study. Ophthalmology. 1981;88:583–600.CrossRef
  20.Pavkov ME, Knowler WC, Lemley KV, Mason CC, Myers BD, Nelson RG. Early renal function decline in type 2 diabetes. Clin J Am Soc Nephrol. 2012;7:78–84.PubMed PubMedCentral CrossRef
  21.Hu A, Luo Y, Guo XB, Ding XY, Zhu XB, Wang XQ, et al. Low serum apolipoprotein A1/B ratio is associated with proliferative diabetic retinopathy in type 2 diabetes. Graefes Arch Clin Exp Ophthalmol. 2012;250:957–62.PubMed CrossRef
  22.Sasongko MB, Wong TY, Nguyen TT, Shaw JE, Jenkins AJ, Wang JJ. Novel versus traditional risk markers for diabetic retinopathy. Diabetologia. 2012;55:666–70.PubMed CrossRef
  23.Deguchi Y, Maeno T, Saishin Y, Hori Y, Shiba T, Takahashi M. Relevance of the serum apolipoprotein ratio to diabetic retinopathy. Jpn J Ophthalmol. 2011;55:128–31.PubMed CrossRef
  24.Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.PubMed CrossRef
  
• 作者单位：Shijie Sun (1) (2)
  Minglong Li (1)
  Jie Zhou (1)
  Zhibo Gai (3)
  Haiyan Shi (4)
  Qing Zhao (4)
  Jun Tian (5)
  
  1. Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong Clinical Medical Center of Endocrinology and Metabolism, Institute of Endocrinology and Metabolism, Shandong Academy of Clinical Medicine, Jinan, 250021, Shandong, China
  2. College of Medicine and Nursing, Dezhou University, Dezhou, 253023, Shandong, China
  3. Department of Clinical Pharmacology and Toxicology, University Hospital, Zurich, 999034, Switzerland
  4. Diabetes Centre, Dezhou People’s Hospital, Dezhou, 253000, Shandong, China
  5. Clinical Laboratory, Dezhou People’s Hospital, Dezhou, 253000, Shandong, China
  
• 刊物主题：Medicine/Public Health, general; General Practice / Family Medicine; Health Administration; Diabetes;
• 出版者：Springer India
• ISSN：1998-3832

文摘

This study aims to identify the predictive value of cystatin C for diabetic retinopathy (DR) in Chinese patients with type 2 diabetes. Data from a cross-sectional hospital-based survey of 450 type 2 diabetes patients were analyzed in the study. DR was assessed by fundus fluorescein angiography. Duration of diabetes and other related information were obtained by questionnaire. Body mass index, blood pressure, HbA_1c, cystatin C, glomerular filtration rate, urinary albumin excretion, blood lipids, and uric acid were measured. Binary logistic regression was performed to evaluate potential risk factors for DR. The predictive value of cystatin C for DR was evaluated using ROC curve. Cystatin C (P = 0.039) was a risk factor for DR after GFR, and other possibly related variables were adjusted. Cystatin C had a significant predictive value for any DR (AUC, 0.763, P < 0.001; optimal cutoff value, 1.11 mg/L; sensitivity, 56.00 %; specificity, 83.90 %) or severe DR (AUC, 0.821, P < 0.001; optimal cutoff value, 1.23 mg/L; sensitivity, 73.60 %; specificity, 88.70 %). Cystatin C is a novel risk factor for DR and should be used to screen and forecast the presence of DR (especially severe DR) in Chinese patients with type 2 diabetes. The association between cystiatin C and DR should not depend on the excellent ability of cystatin C for the estimation of GFR.